Amgen (AMGN) announced that the U.S. FDA has broadened the approved use of Repatha to include adults at increased risk for ...

The US Food and Drug Administration (FDA) has broadened the approved use of Amgen’s Repatha (evolocumab) to include adults at ...

Amgen (AMGN) recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major ...

The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...

The Food and Drug Administration (FDA) has expanded the approval of Repatha ® (evolocumab) to include use in adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse ...

The results are in on an eagerly anticipated trial of a new cholesterol-lowering medicine. Cardiologists are happy with the results.

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

Another PCSK9 inhibitor used for cardiovascular protection, alirocumab (Praluent), remains limited to use in people with ...

Most Medicare Part D and Advantage plans cover Repatha injections. Read about the cost of Repatha after paying the deductible, generic alternatives, and more.